- ICH GCP
- EU: n kliinisten tutkimusten rekisteri
Viimeisimmät kokeilut
EudraCT Number: 2022-003922-27 | Sponsor Protocol Number: PAM-UMCG-002 | Start Date: 2024-02-08 | ||||||
Sponsor Name: University Medical Center Groningen (UMCG) | ||||||||
Full Title: Neo-adjuvant Pembrolizumab as alternative to radio(chemo)therapy in MMRd uterine cancer | ||||||||
Medical condition: Primary uterine cancer characterized with dMMR | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||
Trial protocol: NL (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000356-18 | Sponsor Protocol Number: 25051974 | Start Date: 2023-12-21 | ||||||
Sponsor Name: Stichting Apotheek der Haarlemse Ziekenhuizen | ||||||||
Full Title: Effect of repeated intranasal cobalamin administration on cobalamin deficiency in elderly | ||||||||
Medical condition: Cobalamin (vitamin B12) deficiency | ||||||||
|
||||||||
Population Age: Elderly | Gender: Male, Female | |||||||
Trial protocol: NL (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003146-36 | Sponsor Protocol Number: RIAlta-1 | Start Date: 2023-11-15 | ||||||
Sponsor Name: Vall d'Hebron Research Institute (VHIR) | ||||||||
Full Title: Safety of Rifampicin at High Dose for the Treatment of Adult Subjects with Complex Drug Susceptible Pulmonary and Extrapulmonary Tuberculosis | ||||||||
Medical condition: Pulmonary and extrapulmonary tuberculosis | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: NL (Ongoing) ES (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003804-15 | Sponsor Protocol Number: SGMCBM | Start Date: 2023-11-09 | ||||||||||||||||
Sponsor Name: Leiden University Medical Center | ||||||||||||||||||
Full Title: A FEASIBILITY STUDY OF SGM-101, A FLUOROCHROME-LABELED ANTI-CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY FOR THE INTRAOPERATIVE DETECTION OF COLORECTAL BRAIN METASTASES | ||||||||||||||||||
Medical condition: Colorectal brain metastases | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001632-28 | Sponsor Protocol Number: GENTLE | Start Date: 2023-10-24 | ||||||
Sponsor Name: Rijnstate | ||||||||
Full Title: Ghrelin in anterior circulation stroke and EVT | ||||||||
Medical condition: acute ischemic stroke | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: NL (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003318-35 | Sponsor Protocol Number: VX22-264-101 | Start Date: 2023-09-25 | |||||||||||
Sponsor Name: Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus | |||||||||||||
Medical condition: Type 1 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001287-10 | Sponsor Protocol Number: NBK241/2/2022 | Start Date: 2023-09-22 | |||||||||||
Sponsor Name: Gdański Uniwersytet Medyczny | |||||||||||||
Full Title: Treatment of acute ischemic stroke due to occlusion of a large vessel by mechanical thrombectomy in patients with unknown onset or not meeting the criteria for CT eligibility (ASPECTS | |||||||||||||
Medical condition: acute ischemic stroke caused by occlusion of a large vessel | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-004078-53 | Sponsor Protocol Number: 83403 | Start Date: 2023-08-22 | ||||||
Sponsor Name: Academic Medical Center (AMC), department of Internal Medicine | ||||||||
Full Title: Specifying the anti-inflammatory effects of ziltivekimab with diverse imaging modalities and in-depth cellular phenotyping | ||||||||
Medical condition: - Plaque characteristics - Systemic inflammation | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: NL (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000811-29 | Sponsor Protocol Number: I6T-MC-AMAY | Start Date: 2023-08-16 | |||||||||||
Sponsor Name: Eli Lilly and Company | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn’s Disease (MACARONI-23) | |||||||||||||
Medical condition: Clinical Study to Evaluate Mirikizumab in Pediatric Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) BE (Ongoing) ES (Ongoing) IT (Ongoing) AT (Ongoing) PT (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003063-26 | Sponsor Protocol Number: 1634 | Start Date: 2023-08-10 | |||||||||||
Sponsor Name: European Organisation for Research and Treatment of | |||||||||||||
Full Title: Personalized Risk-Adapted Therapy in Post-Pubertal Patients with Newly Diagnosed Medulloblastoma (PersoMed-I) | |||||||||||||
Medical condition: Newly Diagnosed Medulloblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) DE (Ongoing) IT (Ongoing) NL (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |